不同评分系统在原发性肝癌肝动脉化疗栓塞术预后判断中的应用

汪晓芳; 朱丽影; 卢宝玲; 钟丽华; 程昱; 樊健; 姚红; 于雷

doi:10.3969/j.issn.1001-5256.2017.10.036

不同评分系统在原发性肝癌肝动脉化疗栓塞术预后判断中的应用

DOI: 10.3969/j.issn.1001-5256.2017.10.036

哈尔滨医科大学附属第四医院传染科

基金项目:

国家科技重大专项经费资助(2014ZX10002002)；黑龙江省博士后科研启动金资助(LBH-Q14115)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 1889
- HTML全文浏览量: 46
- PDF下载量: 420
- 被引次数: 0
出版历程
- 收稿日期: 2017-04-28
- 出版日期: 2017-10-20

Application of different scoring systems in evaluating prognosis after transarterial chemoembolization for primary liver cancer

Department of Infectious Diseases, The Fourth Affiliated Hospital of Harbin Medical University

Research funding:

摘要

摘要: 原发性肝癌治疗指南众多,其中巴塞罗那肝癌分期(BCLC)是国际上通常采用的肝癌治疗参考标准,然而只有B期符合肝动脉化疗栓塞术(TACE)的指征,限制了其临床应用。因此,近年来相继提出了评估原发性肝癌TACE治疗预后的评分系统,为原发性肝癌治疗提供重要参考。介绍了有关TACE治疗预后评分系统的应用现状,指出各评分系统的优缺点及评估效能,为肝癌治疗提供理论依据。
- 肝肿瘤 /
- 化学栓塞,治疗性 /
- 预后 /
- 综述
Abstract: There are many treatment guidelines for primary liver cancer, among which Barcelona Clinic Liver Cancer ( BCLC) is commonly used as the reference for the treatment of liver cancer in the world; however, only BCLC stage B patients meet the indication for transarterial chemoembolization ( TACE) , which limits the clinical application of TACE. Therefore, several scoring systems for evaluating prognosis after TACE have been developed in recent years and provide an important reference for the treatment of primary liver cancer. This article introduces the application of scoring systems for evaluating prognosis after TACE and points out their advantages/disadvantages and performance, in order to provide a theoretical basis for the treatment of liver cancer.
- liver neoplasms /
- chemoembolization /
- therapeutic /
- prognosis

HTML全文

参考文献(31)

[1]SU YY, LIU YY, ZHANG YY.Network Meta-analysis of 9 kinds of Chinese herb injections combined with transcatheter arterial chemoembolization in treatment of hepatocellular carcinoma[J].J Jilin Univ:Med Edit, 2016, 42 (6) :1126-1131. (in Chinese) 苏莹莹, 刘莹钰, 张扬雨, 等.9种中药注射剂联合肝动脉插管化疗栓塞术治疗原发性肝癌的网状Meta分析[J].吉林大学学报:医学版, 2016, 42 (6) :1126-1131.

[2]KADALAYIL L, BENINI R, PALLAN L, et al.A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer[J].Ann Oncol, 2013, 24 (10) :2565-2570.

[3]PINATO D J, ARIZUMI T, ALLARA E, et al.Validation of the hepatoma arterial embolization prognostic score in European and A-sian populations and proposed modification[J].Clin Gastroenterol Hepatol, 2014, 13 (6) :1204-1208.e2.

[4]PARK Y, KIM SU, KIM BK, et al.Addition of tumor multiplicity improves the prognostic performance of the hepatoma arterial-embolization prognostic score[J].Liver Int, 2015, 36 (1) :100-107.

[5]CAPPELLI A, CUCCHETTI A, CABIBBO G, et al.Refining prognosis after trans-arterial chemo-embolization for hepatocellular carcinoma[J].Liver Int, 2015, 36 (5) :729-736.

[6]LLADO L, VIRGILI J, FIGUERAS J, et al.A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization[J].Cancer, 2000, 88 (1) :50-57.

[7]O'SUILLEABHAIN CB, POON RT, YONG JL, et al.Factors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma[J].Br J Surg, 2003, 90 (3) :325-331.

[8]HU H, HAN XK, LONG XR, et al.Prognostic nomogram for post-surgical treatment with adjuvant TACE in hepatitis B virus-related hepatocellular carcinoma[J].Oncotarget, 2016, 7 (36) :58302-58314.

[9]WHITE JA, REDDEN DT, BRYANT MK, et al.Predictors of repeat transarterial chemoembolization in the treatment of hepatocellular carcinoma[J].HPB (Oxford) , 2014, 16 (12) :1095-1101.

[10]EDGE SB, BYRD DR, COMPTON CC, et al.AJCC cancer staging manual[M].7th ed.New York:Springer, 2010:191-200.

[11]The Cancer of the Liver Italian Program (CLIP) Investigators.Prospective validation of the CLIP score:a new prognostic system for patients with cirrhosis and hepatocellularcarcinoma[J].Hepatology, 2000, 31 (4) :840-845.

[12]BRUIX J, SHERMAN M, American Association for the Study of Liver Diseases.Management of hepatocellular carcinoma:an update[J].Hepatology, 2011, 53 (3) :1020-1022.

[13]PINATO DJ, ARIZUMI T, JANG J W, et al.P0383:Combined sequential use of HAP and ART scores to predict transarterial chemoembolization failure in hepatocellular carcinoma:a multi-center comparative study[J].J Hepatol, 2015, 62 (1) :s456.

[14]HUCKE F, PINTER M, GRAZIADEI I, et al.How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma[J].J Hepatol, 2014, 61 (6) :1287-1296.

[15]REKIK S, GUYOT E, BHAIS M, et al.The CRP level and STATEscore predict survival in cirrhotic patients with hepatocellular carcinoma treated by transarterial embolization[J].Dig Liver Dis, 2016, 48 (9) :1088.

[16]DI MARTINO V, COUTRIS C, CERVONI JP, et al.Prognostic value of C-reactive protein levels in patients with cirrhosis[J].Liver Transpl, 2015, 21 (6) :753-760.

[17]SIEGHART W, HUCKE F, PINTER M, et al.The ART of decision making:retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma[J].Hepatology, 2013, 57 (6) :2261-2273.

[18]MHRINGER-KUNZ A, KLOECKNER R, PITTON MB, et al.Validation of the risk prediction models STATE-score and START-strategy to guide TACE treatment in patients with hepatocellular carcinoma[J].Cardiovasc Intervent Radiol, 2017, 40 (7) :1017-1025.

[19]OGASAWARA S, CHIBA T, OOKA Y, et al.A prognostic score for patients with intermediate-stage hepatocellular carcinoma treated with transarterial chemoembolization[J].PLo S One, 2014, 10 (4) :e0125244.

[20]KIM BK, SHIM JH, KIM SU, et al.Risk prediction for patients with hepatocellular carcinoma undergoing chemoembolization:development of a prediction model[J].Liver Int, 2015, 36 (1) :92-99.

[21]LENCIONI R, LLOVET JM.Modified RECIST (mRECIST) assessment for hepatocellular carcinoma[J].Semin Liver Dis, 2010, 30 (1) :52-60.

[22]SHIM JH, LEE HC, KIM SO, et al.Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization?A validation study of old and new models[J].Radiology, 2012, 262 (2) :708-718.

[23]KIM BK, KIM KA, PARK JY, et al.Prospective comparison of prognostic values of modified Response Evaluation Criteria in solid tumours with European Association for the Study of the liver criteria in hepatocellular carcinoma following chemoembolisation[J].Eur JCancer, 2013, 49 (4) :826-834.

[24]JUNG ES, KIM JH, YOON EL, et al.Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemo-embolization[J].J Hepatol, 2013, 58 (6) :1181-1187.

[25]HA Y, LEE JB, JU HS, et al.Validation and reappraisal of the assessment for retreatment with transarterial chemoembolization score for unresectable non-metastatic hepatocellular carcinoma in a hepatitis b virus-endemic region[J].Eur Radiol, 2016, 26 (10) :1-9.

[26]CHEN L, NI CF, CHEN SX, et al.A modified model for assessment for retreatment with transarterial chemoembolization in Chinese hepatocellular carcinoma patients[J].J Vasc Interv Radiol, 2016, 27 (9) :1288-1297.

[27]HUCKE F, SIEGHART W, PINTER M, et al.The ART strategy:sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE[J].J Hepatol, 2013, 60 (1) :118-126.

[28]BROWN DB, GESCHWIND JF, SOULEN MC, et al.Society of Interventional Radiology position statement on chemoembolization of hepatic malignancies[J].J Vasc Interv Radiol, 2006, 17 (2 Pt 1) :217-223.

[29]ADHOUTE X, PENARANDA G, NAUDE S, et al.Retreatment with TACE:The ABCR SCORE, an aid to the decision-making process[J].J Hepatol, 2015, 62 (4) :855-862.

[30]LUO J, GUO RP, LAI EC, et al.Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis:a prospective comparative study[J].Ann Surg Oncol, 2011, 18 (2) :413-420.

[31]ZHOU DS, XU L, LUO YL, et al.Inflammation scores predict survival for hepatitis B virus-related hepatocellular carcinoma patients after transarterial chemoembolization[J].World J Gastroenterol, 2015, 21 (18) :5582-5590.

施引文献

资源附件(0)

访问统计